NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Celularity Inc (NASDAQ: CELUW)

 
CELUW Technical Analysis
3
As on 24th Jan 2025 CELUW STOCK Price closed @ 0.08 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.04 & Buy for SHORT-TERM with Stoploss of 0.06 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

CELUWSTOCK Price

Open 0.03 Change Price %
High 0.11 1 Day 0.05 166.67
Low 0.03 1 Week 0.05 166.67
Close 0.08 1 Month 0.06 300.00
Volume 269868 1 Year 0.02 33.33
52 Week High 0.10 | 52 Week Low 0.00
 
NASDAQ USA Most Active Stocks
AMRS 0.14 100.00%
GOEV 0.48 45.45%
NVDA 142.62 -3.12%
TNXP 0.38 15.15%
LMDX 0.02 0.00%
AKTS 0.04 0.00%
LCID 2.79 2.57%
PLUG 2.08 -0.48%
PONO 1.72 2.38%
TELL 1.00 0.00%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
YI 5.28 1023.40%
CTXRW 0.14 600.00%
ZVZZT 91.86 237.35%
NDRAW 0.03 200.00%
CELUW 0.08 166.67%
ZWZZT 23.88 162.42%
GDEVW 0.05 150.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
TFFP 0.06 -62.50%
MILEW 0.06 -53.85%
LOTZW 0.01 -50.00%
HYMCL 0.01 -50.00%
BTAQW 0.01 -50.00%
 
 
CELUW
Daily Charts
CELUW
Intraday Charts
Whats New @
Bazaartrend
CELUW
Free Analysis
 
CELUW Important Levels Intraday
RESISTANCE0.23
RESISTANCE0.18
RESISTANCE0.15
RESISTANCE0.12
SUPPORT0.04
SUPPORT0.01
SUPPORT-0.02
SUPPORT-0.07
 
CELUW Forecast January 2025
4th UP Forecast0.33
3rd UP Forecast0.25
2nd UP Forecast0.2
1st UP Forecast0.15
1st DOWN Forecast0.01
2nd DOWN Forecast-0.04
3rd DOWN Forecast-0.09
4th DOWN Forecast-0.17
 
CELUW Weekly Forecast
4th UP Forecast0.16
3rd UP Forecast0.13
2nd UP Forecast0.12
1st UP Forecast0.10
1st DOWN Forecast0.06
2nd DOWN Forecast0.04
3rd DOWN Forecast0.03
4th DOWN Forecast0.00
 
CELUW Forecast2025
4th UP Forecast0.39
3rd UP Forecast0.29
2nd UP Forecast0.23
1st UP Forecast0.17
1st DOWN Forecast-0.01
2nd DOWN Forecast-0.07
3rd DOWN Forecast-0.13
4th DOWN Forecast-0.23
 
 
CELUW Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
CELUW Address
CELUW
 
CELUW Latest News
 
Your Comments and Response on Celularity Inc
 
CELUW Business Profile
Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic T cell therapies. It operates through Cell Therapy, Degenerative Disease, and BioBanking. Its lead therapeutic programs include CYCART-19, an allogeneic CAR-T therapy, which is in pre-clinical stage for the treatment of B-cell malignancies; CYNK-001, an allogeneic unmodified natural killer (NK) cell that is in Phase 1 clinical trial to treat acute myeloid leukemia, as well as in Phase 1/2a clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell to treat HER2+ gastric cancer; and APPL-001, a placenta-derived mesenchymal-like adherent stromal cell for the treatment of crohn's disease. The company also sells and licenses products used in surgical and wound care markets, such as Biovance and Interfyl; and collects stem cells from umbilical cords and placentas and provides cells storage under the LifebankUSA brand. Celularity Inc. was incorporated in 2016 and is based in Florham Park, New Jersey. Address: 170 Park Avenue, Florham Park, NJ, United States, 07932
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service